| Literature DB >> 24643046 |
Bouabid Badaoui1, Teresa Rutigliano1, Anna Anselmo1, Merijn Vanhee2, Hans Nauwynck2, Elisabetta Giuffra1, Sara Botti1.
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) mainly infects porcine alveolar macrophages (PAMs), resulting in porcine reproductive and respiratory syndrome (PRRS) in pigs. Most of the transcriptomic studies on PAMs infected with PRRSV conducted thus far have made use of microarray technology. Here, we investigated the transcriptome of PAMs in vitro at 12 h post-infection with two European PRRSV strains characterized by low (Lelystad, LV) and high (Lena) virulence through RNA-Seq. The expression levels of genes, isoforms, alternative transcription start sites (TSS) and differential promoter usage revealed a complex pattern of transcriptional and post-transcriptional gene regulation upon infection with the two strains. Gene ontology analysis confirmed that infection of PAMs with both the Lena and LV strains affected signaling pathways directly linked to the innate immune response, including interferon regulatory factors (IRF), RIG1-like receptors, TLRs and PKR pathways. The results confirmed that interferon signaling is crucial for transcriptional regulation during PAM infection. IFN-β1 and IFN-αω, but not IFN-α, were up-regulated following infection with either the LV or Lena strain. The down-regulation of canonical pathways, such as the interplay between the innate and adaptive immune responses, cell death and TLR3/TLR7 signaling, was observed for both strains, but Lena triggered a stronger down-regulation than LV. This analysis contributes to a better understanding of the interactions between PRRSV and PAMs and outlines the differences in the responses of PAMs to strains with different levels of virulence, which may lead to the development of new PRRSV control strategies.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24643046 PMCID: PMC3958415 DOI: 10.1371/journal.pone.0091918
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Venn diagram illustrating the significantly affected genes (I), isoforms (II), TSSs (III) and differential promoter use (VI) found in the LV vs. mock (A), Lena vs. mock (B) and LV vs. Lena (C) comparisons.
I. Venn diagram illustrating the significantly affected genes found in the LV vs. mock (A, 446), Lena vs. mock (B, 153) and LV vs. Lena (C, 241) comparisons. II. Venn diagram illustrating the significantly affected isoforms found in the LV vs. mock (A, 187), Lena vs. mock (B, 72) and LV vs. Lena (C, 34) comparisons. III. Venn diagram illustrating the significantly affected TSSs found in the LV vs. mock (A, 240), Lena vs. mock (B, 93) and LV vs. Lena (C, 50) comparisons. VI. Venn diagram illustrating the significantly affected promoters found in the LV vs. mock (A, 14), Lena vs. mock (B, 6) and LV vs. Lena (C, 7) comparisons. The blue circle, “A”, corresponds to the LV vs. mock case (I. significantly affected genes, II. significantly affected isoforms, III. significantly affected TSSs and VI. significantly affected promoters). The green circle, “B”, corresponds to the Lena vs. mock case (I. significantly affected genes, II. significantly affected isoforms, III. significantly affected TSSs and VI. significantly affected promoters). The purple circle, “C”, corresponds to the LV vs. Lena case (I. significantly affected genes, II. significantly affected isoforms, III. significantly affected TSSs and VI. significantly affected promoters).
Figure 2Venn diagram illustrating the significantly affected genes (A, chartreuse color), isoforms (B, violet color) and differential promoter use (C, orange color) found in the LV vs. mock (I), Lena vs. mock (II) and LV vs. Lena (III) comparisons.
I. Venn diagram illustrating the significantly affected genes (A, 446), isoforms (B, 187) and differential promoter use (C, 14) found in the LV vs. mock comparison. II. Venn diagram illustrating the significantly affected genes (A, 153), isoforms (B, 72) and promoters (C, 6) found in Lena vs. mock comparison. III. Venn diagram illustrating the significantly affected genes (A, 241), isoforms (B, 34) and promoters (C, 7) found in LV vs. Lena comparison. The chartreuse circle, “A”, corresponds to the differentially expressed genes (I. LV vs. mock, II. Lena vs. mock and III. LV vs. Lena). The violet circle, “B”, represents the differentially expressed isoforms (I. LV vs. mock, II. Lena vs. mock and III. LV vs. Lena). The orange circle, “C”, corresponds to the differentially used promoters(I. LV vs. mock, II. Lena vs. mock and III. LV vs. Lena).
Lists of the 5 top canonical pathways and the corresponding affected genes in the LV vs. mock (A), Lena vs. mock (B) and LV vs. Lena (C) comparisons.
| A. LV | |||
| Ingenuity Canonical Pathways | −log(p-value) | Ratio | Molecules |
| Interferon Signaling | 1.08E+01 | 3.87E-01 | IFIT3,SOCS1,IFIT1,OAS1,MX1,IFNB1, IFITM1,STAT2,PSMB8,JAK2,STAT1,IRF1 |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 9.97E+00 | 2.64E-01 | DHX58,IL10,ZBP1,IFNB1,ADAR,ISG15, IFIH1,IRF7,NFKBIA,DDX58,STAT2,IFIT2, STAT1,TNF |
| Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses | 8.55E+00 | 1.78E-01 | OAS1,OAS2,IL10,PIK3R1,IFNB1,RNASEL,IFIH1,IRF7,DDX58,TLR7,CASP1,IL1B,PIK3CD, EIF2AK2,TLR3,TNF |
| Role of PKR in Interferon Induction and Antiviral Response | 7.03E+00 | 2.5E-01 | NFKBIA,IFNB1,BID,EIF2AK2,TLR3,STAT1, CASP8,RNASEL,TNF,IRF1 |
| Retinoic Acid Mediated Apoptosis Signaling | 6.96E+00 | 2.16E-01 | BID,CASP8,IFNB1,IRF1,PARP9,PARP11, PARP14,TIPARP,TNFRSF10A,TNFSF10, ZC3HAV1 |
*probability that a canonical pathway is significantly involved in the analysis.
number of genes in the list involved in a certain canonical pathway divided by the number of genes in the IPA database involved in the same canonical pathway.
genes involved in the corresponding canonical pathway.
Figure 3Gene expression of IFN-β and IFN-αω genes in FPKM (Y axis).
Top left: IFN-β expression in the mock, LV and Lena groups. IFN-β was differentially expressed between both the LV and Lena groups when compared to the mock infection group. IFN-β was also expressed at a significantly higher level in the LV group than in the Lena group. Lower right: IFN-αω expression in the mock, LV and Lena groups. IFN-αω was differentially expressed between the LV and Lena groups from one side and the mock group from the other side. IFN-β was also expressed at a significantly higher level in the LV group than in the Lena group.
Lists of affected biological functions and the corresponding affected genes in the LV vs. mock (A) and Lena vs. mock (B) comparisons.
| A. LV | ||||
| Function Annotation | p-Value | Predicted Activation State | Activation z-score | Molecules |
|
| ||||
| cell death of immune cells | 1.89E-13 | Increased | 2.147 | BID,CASP1, CASP8, CCL4, CCR5, CD274, CD38, CD5, DHX58, EIF2AK2, HAVCR2, HCAR2, HSH2D, IDO1, IFNB1, IL10, IL15, IL15RA, IL1B, IL27, IL7R, IRF1, IRF2, IRF4, JAK2, LGALS9, MCL1, MX1, NAMPT, NFKBIA, PARP14, PIK3CD, PIK3R1, PIM1, PMAIP1, PPBP, PRDM1, PYCARD, RHOH, RNASEL, SEMA4D, SOCS1, STAT1, TLR3, TNF, TNFAIP3, TNFSF10, TNFSF13B |
| quantity of leukocytes | 2.62E-13 | Increased | 2.297 | ABCA1, ARNTL, B3GNT5, BID, CASP8, CCL2, CCL3L1/CCL3L3, CCR2, CCR5, CD274, CD38, CD5, CXCL10, CYP27B1, DAPP1, DDX58, ELF1, ENTPD7, HAVCR2, HBEGF, HLA-B, IDO1, IFNB1, IL10, IL15, IL15RA, IL1B, IL27, IL7R, IRF1, IRF2, IRF4, ISG15, JAK2, LGALS9, MAEA, MAP3K8, MCL1, MXD1, NBN, NFKBIA, PDE4B, PIK3CD, PIK3R1, PIM1, PIM3, PLAC8, PML, PPM1D, PRDM1, PTPN13, PYCARD, RFX5, RHOH, RICTOR, SEMA4D, SOCS1, SOX4, STAT1, TCF4, TEC, TIMD4, TLR3, TNF, TNFAIP3, TNFRSF10A, TNFSF10, TNFSF13B, VCAM1 |
| Cell death | 2.62E-13 | Increased | 2.297 | ABCA1, ARNTL, B3GNT5, BID, CASP8, CCL2, CCL3L1/CCL3L3, CCR2, CCR5, CD274, CD38, CD5, CXCL10, CYP27B1, DAPP1, DDX58, ELF1, ENTPD7, HAVCR2, HBEGF, HLA-B, IDO1, IFNB1, IL10, IL15, IL15RA, IL1B, IL27, IL7R, IRF1, IRF2, IRF4, ISG15, JAK2, LGALS9, MAEA, MAP3K8, MCL1, MXD1, NBN, NFKBIA, PDE4B, PIK3CD, PIK3R1, PIM1, PIM3, PLAC8, PML, PPM1D, PRDM1, PTPN13, PYCARD, RFX5, RHOH, RICTOR, SEMA4D, SOCS1, SOX4, STAT1, TCF4, TEC, TIMD4, TLR3, TNF, TNFAIP3, TNFRSF10A, TNFSF10, TNFSF13B, VCAM1 |
| quantity of lymphocytes | 1.61E-12 | Increased | 2.703 | BID, CASP1, CASP8, CCL2, CCL4, CCR5, CD274, CD38, CD5, DHX58, EIF2AK2, HAVCR2, HCAR2, HLA-B, HSH2D, IDO1, IFNB1, IL10, IL15, IL15RA, IL1B, IL27, IL7R, IRF1, IRF2, IRF4, JAK2, LGALS9, MCL1, MX1, NAMPT, NFKBIA, PARP14, PIK3CD, PIK3R1, PIM1, PMAIP1, PPBP, PRDM1, PYCARD, RHOH, RNASEL, SEMA4D, SOCS1, STAT1, TLR3, TNF, TNFAIP3, TNFSF10, TNFSF13B |
| quantity of mononuclear leukocytes | 5.16E-12 | Increased | 3.212 | ARNTL, B3GNT5, BID, CASP8, CCL2, CCR2, CCR5, CD274, CD38, CD5, CXCL10, CYP27B1, DAPP1, DDX58, ELF1, ENTPD7, HLA-B, IFNB1, IL10, IL15, IL15RA, IL27, IL7R, IRF1, IRF2, IRF4, ISG15, JAK2, LGALS9, MAP3K8, MCL1, NBN, NFKBIA, PIK3CD, PIK3R1, PIM1, PIM3, PPM1D, PRDM1, PTPN13, PYCARD, RFX5, RHOH, SEMA4D, SOCS1, SOX4, STAT1, TCF4, TEC, TIMD4, TLR3, TNF, TNFAIP3, TNFRSF10A, TNFSF13B, VCAM1 |
| infection of leukocytes | 5.16E-12 | Increased | 3.212 | ARNTL, B3GNT5, BID, CASP8, CCL2, CCR2, CCR5, CD274, CD38, CD5, CXCL10, CYP27B1, DAPP1, DDX58, ELF1, ENTPD7, HLA-B, IFNB1, IL10, IL15, IL15RA, IL27, IL7R, IRF1, IRF2, IRF4, ISG15, JAK2, LGALS9, MAP3K8, MCL1, NBN, NFKBIA, PIK3CD, PIK3R1, PIM1, PIM3, PPM1D, PRDM1, PTPN13, PYCARD, RFX5, RHOH, SEMA4D, SOCS1, SOX4, STAT1, TCF4, TEC, TIMD4, TLR3, TNF, TNFAIP3, TNFRSF10A, TNFSF13B, VCAM1 |
| proliferation of B lymphocytes | 7.80E-12 | Increased | 3.218 | ARNTL, B3GNT5, BID, CASP8, CCL2, CCR2, CCR5, CD274, CD38, CD5, CXCL10, CYP27B1, DAPP1, DDX58, ELF1, ENTPD7, HLA-B, IFNB1, IL10, IL15, IL15RA, IL27, IL7R, IRF1, IRF2, IRF4, ISG15, JAK2, LGALS9, MAP3K8, MCL1, NBN, NFKBIA, PIK3CD, PIK3R1, PIM1, PIM3, PML, PPM1D, PRDM1, PTPN13, PYCARD, RFX5, RHOH, SEMA4D, SOCS1, SOX4, STAT1, TCF4, TEC, TIMD4, TLR3, TNF, TNFAIP3, TNFRSF10A, TNFSF13B, VCAM1 |
| quantity of T lymphocytes | 7.80E-12 | Increased | 3.218 | ARNTL, B3GNT5, BID, CASP8, CCL2, CCR2, CCR5, CD274, CD38, CD5, CXCL10, CYP27B1, DAPP1, DDX58, ELF1, ENTPD7, HLA-B, IFNB1, IL10, IL15, IL15RA, IL27, IL7R, IRF1, IRF2, IRF4, ISG15, JAK2, LGALS9, MAP3K8, MCL1, NBN, NFKBIA, PIK3CD, PIK3R1, PIM1, PIM3, PML, PPM1D, PRDM1, PTPN13, PYCARD, RFX5, RHOH, SEMA4D, SOCS1, SOX4, STAT1, TCF4, TEC, TIMD4, TLR3, TNF, TNFAIP3, TNFRSF10A, TNFSF13B, VCAM1 |
| apoptosis of phagocytes | 1.47E-10 | Decreased | −2.201 | CASP1, CCL4, CCR5, EIF2AK2, HAVCR2, IL15, IRF1, LGALS9, MGLL, PIK3R1, SAMHD1, STAT1, TNF |
| Cellular homeostasis | 1.47E-10 | Decreased | −2.201 | CASP1, CCL4, CCR5, EIF2AK2, HAVCR2, IL15, IRF1, LGALS9, MGLL, PIK3R1, SAMHD1, STAT1, TNF |
|
| ||||
| cell death of immune cells | 4.78E-08 | Increased | 2.276 | CCL4, CCR5, CD274, DHX58, EIF2AK2, HAVCR2, HCAR2, IFNB1, IL15RA, IL27, IL7R, IL8, MX1, PARP14, PIK3CD, PPBP, RNASEL, SOCS1, TNF, TNFSF10 |
| Cell death | 8.23E-08 | Increased | 2.575 | CCL2, CCL4, CCR5, CD274, DHX58, EIF2AK2, HAVCR2, HCAR2, IFNB1, IL15RA, IL27, IL7R, IL8, MX1, PARP14, PIK3CD, PPBP, RNASEL, SOCS1, TNF, TNFSF10 |
| Cell death of lymphocytes | 6.11E-07 | Increased | 2.921 | CCL2, CCL4, CCL8, CCR5, CCRL2, CXCL10, EDN1, IFNB1, IL8, PDE4B, PIK3CD, PPBP, TNF |
| apoptosis of lymphocytes | 6.11E-07 | Increased | 2.921 | CCL2, CCL4, CCL8, CCR5, CCRL2, CXCL10, EDN1, IFNB1, IL8, PDE4B, PIK3CD, PPBP, TNF |
| apoptosis of T lymphocytes | 6.11E-07 | Increased | 2.921 | CCL2, CCL4, CCL8, CCR5, CCRL2, CXCL10, EDN1, IFNB1, IL8, PDE4B, PIK3CD, PPBP, TNF |
| invasion of phagocytes | 6.11E-07 | Increased | 2.921 | CCL2, CCL4, CCL8, CCR5, CCRL2, CXCL10, EDN1, IFNB1, IL8, PDE4B, PIK3CD, PPBP, TNF |
| chemotaxis of antigen presenting cells | 2.43E-06 | Increased | 2.987 | ADAR, CCL2, CD274, DDX58, DUSP5, EIF2AK2, IFNB1, IL15RA, IL27, IL7R, IL8, IRF7, JAG1, PIK3CD, PML, RSAD2, SEMA4A, SOCS1, TNF |
| hematopoiesis of myeloid progenitor cells | 2.43E-06 | Increased | 2.987 | ADAR, CCL2, CD274, DDX58, DUSP5, EIF2AK2, IFNB1, IL15RA, IL27, IL7R, IL8, IRF7, JAG1, PIK3CD, PML, RSAD2, SEMA4A, SOCS1, TNF |
| cell movement of PBMCs | 2.43E-06 | Increased | 2.987 | ADAR, CCL2, CD274, DDX58, DUSP5, EIF2AK2, IFNB1, IL15RA, IL27, IL7R, IL8, IRF7, JAG1, PIK3CD, PML, RSAD2, SEMA4A, SOCS1, TNF |
| inflammatory response | 2.53E-06 | Increased | 2.635 | CCL2, CCL4, CCL8, CCR5, CXCL10, IFNB1, IL8, PIK3CD |
*probability that a biological function is significantly involved in the analysis.
activation state of the biological function; three cases are possible: activation, inhibition or “none”, if the statistical significance is not sufficient for a clear conclusion regarding the activation/inhibition.
prediction of the activation state of the biological function; IPA uses z-scores to evaluate the activation/inhibition of the biological function. A negative score is indicative of inhibition, while a positive score is indicative of activation. If the statistical significance is not sufficient for a clear conclusion regarding activation/inhibition, we discuss the tendency toward activation/inhibition on the basis of the positive/negative activation z-score.
genes involved in the corresponding biological function.